# Eli Lilly (LLY) — News

LLY · NYSE · Stock

Canonical page: https://www.lighthorse.io/tickers/lly/news

## Recent headlines

- [Novo Nordisk CEO: We will launch next waves of diabetes and obesity innovations long before the loss of exclusivity](https://www.ainvest.com/news/novo-nordisk-ceo-launch-waves-diabetes-obesity-innovations-long-loss-exclusivity-2609) — AInvest Wire, Sep 21, 2026
  Novo Nordisk has emphasized its commitment to maintaining a leadership position in the diabetes and obesity markets through a pipeline of upcoming innovations. The company’s CEO has stated that new product launches will occur well before the expiration of current exclusivity periods, aiming to…
- [Novo CEO says 2035 pipeline sales target is 'risk-adjusted'](https://www.ainvest.com/news/novo-ceo-2035-pipeline-sales-target-risk-adjusted-2609) — AInvest Wire, Sep 21, 2026
  Novo Nordisk CEO Mike Doustdar emphasized the company’s 2035 pipeline sales target is based on a “risk-adjusted” approach during a recent interview, underscoring strategic acquisitions and partnerships . The CEO highlighted Novo’s active engagement in business development, noting that the company…
- [Insilico enters into an AI co-development collaboration](https://www.ainvest.com/news/insilico-enters-ai-development-collaboration-2609) — AInvest Wire, Sep 21, 2026
  Insilico Medicine (HKEX: 3696) has entered into two significant AI-driven drug discovery collaborations in recent months, expanding its strategic partnerships in the biopharmaceutical sector. The first collaboration involves Takeda, under which Insilico will leverage its Pharma.AI platform to…
- [Novo investors urge company to pursue deals and expand its drug pipeline - FT](https://www.ainvest.com/news/novo-investors-urge-company-pursue-deals-expand-drug-pipeline-ft-2609) — AInvest Wire, Sep 20, 2026
  Investors in Novo Nordisk are increasingly calling for the company to pursue large-scale acquisitions and strategic partnerships to diversify its drug pipeline and reduce dependence on its flagship GLP-1-based therapies , such as Wegovy and Ozempic. With the looming patent expiry for semaglutide…
- **Important** — [Trex Bio - Eli Lilly indicates interest in purchasing up to 19.9% of Trex Bio common stock - SEC filing](https://www.ainvest.com/news/trex-bio-eli-lilly-interest-purchasing-19-9-trex-bio-common-stock-sec-filing-2609) — AInvest Wire, Sep 18, 2026

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).